Pyc Therapeutics Ltd has released a press release.
Interim Update on Progress in RP11 Repeat Dose Trials
Filed with ASX ·
6ix hasn’t read this filing yet.
PYC Therapeutics Limited on 6ix
Earlier from PYC Therapeutics
- US FDA Grants Orphan Drug Designation to PYC Drug Candidate
- Notice of Annual General Meeting/Proxy Form
- FDA Grants Rare Pediatric Disease Designation to PYC-001
- Appendix 4E and Audited Financial Statements
- PYC to Start Human Trials in Second Blinding Eye Disease
Later from PYC Therapeutics
- First ADOA Patient Dosed in Clinical Trial
- RP11 SRC Approves Dose Escalation to Final Patient Cohort
- Consolidation/Split - PYC
- PYC to Progress Kidney Drug Candidate Into Human Trials
- PYC Nominates Fourth Clinical Drug Candidate in PMS Program
Follow PYC Therapeutics into a list and get an email when it puts out news.
Follow PYC Therapeutics